Compare Stocks: PHMMF, IOVA, RYTM, and LGND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$8.48 -11.3%	$11.37	$1.76 ▼ $15.37	$4.33B	0.76	13.86 million shs	31.14 million shs
LGND Ligand Pharmaceuticals	$322.75 +1.7%	$296.39	$175.89 ▼ $326.63	$6.43B	1.14	226,438 shs	344,299 shs
PHMMF Pharma Mar	$77.09	$93.11	$77.09 ▼ $106.48	$1.39B	0.74	31 shs	N/A
RYTM Rhythm Pharmaceuticals	$92.57 -0.5%	$97.18	$74.50 ▼ $122.20	$6.38B	2.01	672,589 shs	431,654 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	-11.30%	-39.82%	-42.78%	+108.35%	+324.00%
LGND Ligand Pharmaceuticals	+1.71%	+6.33%	+3.32%	+12.25%	+74.91%
PHMMF Pharma Mar	0.00%	-18.51%	-18.51%	-10.45%	-17.11%
RYTM Rhythm Pharmaceuticals	-0.54%	+3.70%	-2.77%	-6.73%	-18.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IOVA Iovance Biotherapeutics	$8.48 -11.3%	$11.37	$1.76 ▼ $15.37	$4.33B	0.76	13.86 million shs	31.14 million shs
LGND Ligand Pharmaceuticals	$322.75 +1.7%	$296.39	$175.89 ▼ $326.63	$6.43B	1.14	226,438 shs	344,299 shs
PHMMF Pharma Mar	$77.09	$93.11	$77.09 ▼ $106.48	$1.39B	0.74	31 shs	N/A
RYTM Rhythm Pharmaceuticals	$92.57 -0.5%	$97.18	$74.50 ▼ $122.20	$6.38B	2.01	672,589 shs	431,654 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IOVA Iovance Biotherapeutics	-11.30%	-39.82%	-42.78%	+108.35%	+324.00%
LGND Ligand Pharmaceuticals	+1.71%	+6.33%	+3.32%	+12.25%	+74.91%
PHMMF Pharma Mar	0.00%	-18.51%	-18.51%	-10.45%	-17.11%
RYTM Rhythm Pharmaceuticals	-0.54%	+3.70%	-2.77%	-6.73%	-18.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IOVA Iovance Biotherapeutics	2.71	Moderate Buy	$13.20	55.66% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$339.22	5.10% Upside
PHMMF Pharma Mar	3.00	Buy	N/A	N/A
RYTM Rhythm Pharmaceuticals	2.77	Moderate Buy	$142.50	53.94% Upside

Current Analyst Ratings Breakdown

Latest PHMMF, IOVA, RYTM, and LGND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/30/2026	LGND Ligand Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$345.00 ➝ $357.00
10/26/2026	IOVA Iovance Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
10/16/2026	RYTM Rhythm Pharmaceuticals	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform
10/15/2026	RYTM Rhythm Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$146.00 ➝ $145.00
10/13/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$15.00 ➝ $18.00
10/12/2026	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$105.00 ➝ $130.00
10/8/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Outperform	$155.00 ➝ $159.00
10/8/2026	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$6.00 ➝ $11.00
9/30/2026	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$14.00 ➝ $18.00
9/29/2026	IOVA Iovance Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)

(Data available from 10/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IOVA Iovance Biotherapeutics	$263.50M	14.58	N/A	N/A	$1.76 per share	4.82
LGND Ligand Pharmaceuticals	$290.54M	22.15	$7.99 per share	40.41	$48.24 per share	6.69
PHMMF Pharma Mar	$250.42M	5.54	$0.41 per share	186.12	N/A	∞
RYTM Rhythm Pharmaceuticals	$189.76M	33.43	N/A	N/A	$2.08 per share	44.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$2.24	144.08	38.65	2.54	20.27%	5.22%	2.74%	N/A
PHMMF Pharma Mar	$84.84M	N/A	N/A	36.02	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)

Latest PHMMF, IOVA, RYTM, and LGND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	IOVA Iovance Biotherapeutics	-$0.0846	N/A	N/A	N/A	$115.53 million	N/A
11/3/2026	Q3 2026	RYTM Rhythm Pharmaceuticals	-$0.7097	N/A	N/A	N/A	$85.57 million	N/A
10/29/2026	Q3 2026	LGND Ligand Pharmaceuticals	$2.33	$2.67	+$0.34	-$1.43	$77.00 million	$78.75 million
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHMMF Pharma Mar	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IOVA Iovance Biotherapeutics	N/A	4.34	3.82
LGND Ligand Pharmaceuticals	1.17	13.35	30.96
PHMMF Pharma Mar	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IOVA Iovance Biotherapeutics	77.03%
LGND Ligand Pharmaceuticals	91.28%
PHMMF Pharma Mar	N/A
RYTM Rhythm Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
IOVA Iovance Biotherapeutics	7.80%
LGND Ligand Pharmaceuticals	5.60%
PHMMF Pharma Mar	1.88%
RYTM Rhythm Pharmaceuticals	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable
LGND Ligand Pharmaceuticals	47	19.94 million	18.82 million	Optionable
PHMMF Pharma Mar	509	18.00 million	17.66 million	Not Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable

PHMMF, IOVA, RYTM, and LGND Headlines

Recent News About These Companies

Citi Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)

October 29 at 2:24 PM | theglobeandmail.com

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

October 27, 2026 | zacks.com

Rhythm Pharmaceuticals (RYTM) Projected to Post Earnings on Tuesday

October 27, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. (RYTM) - What Are Brokerages Saying About This Stock?

October 25, 2026 | americanbankingnews.com

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.50 According to Brokerages

October 25, 2026 | marketbeat.com

William Blair initiates coverage of Rhythm Pharmaceuticals at outperform

October 22, 2026 | msn.com

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

October 21, 2026 | globenewswire.com

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech with 67% Upside Potential

October 19, 2026 | directorstalkinterviews.com

176,882 Rhythm Pharmaceuticals, Inc. $RYTM Shares Purchased by Assenagon Asset Management S.A.

October 18, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. $RYTM Stock Sold by Aspiriant LLC

October 18, 2026 | marketbeat.com

JPMorgan cuts target for Rhythm Pharmaceuticals stock to USD 145.00

October 15, 2026 | ad-hoc-news.deA

JPMorgan Chase & Co. Has Lowered Expectations for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

October 15, 2026 | marketbeat.com

Rhythm Pharmaceuticals, Inc. Announces Commercial Launch of IMCIVREE® (Setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

October 14, 2026 | marketscreener.comM

Rhythm launches IMCIVREE in Japan

October 14, 2026 | grafa.comG

Rhythm Launches Imcivree In Japan For Acquired Hypothalamic Obesity

October 14, 2026 | rttnews.com

HC Wainwright Has Positive Outlook for RYTM Q3 Earnings

October 14, 2026 | marketbeat.com

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

October 13, 2026 | globenewswire.com

Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should Know

October 13, 2026 | zacks.com

How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Progress In Prader-Willi And Genetically Defined Obesity Therapies

October 13, 2026 | finance.yahoo.com

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech Contender with 52.99% Upside Potential

October 12, 2026 | directorstalkinterviews.com

Rhythm's Imcivree Launch in Hypothalamic Obesity Encouraging, RBC Says

October 9, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHMMF, IOVA, RYTM, and LGND Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

$8.48 -1.08 (-11.30%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$8.46 -0.02 (-0.24%)

As of 10/30/2026 07:59 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Ligand Pharmaceuticals NASDAQ:LGND

$322.75 +5.42 (+1.71%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$322.02 -0.73 (-0.22%)

As of 10/30/2026 07:38 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Pharma Mar OTCMKTS:PHMMF

$77.09 0.00 (0.00%)

As of 10/30/2026

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.

Rhythm Pharmaceuticals NASDAQ:RYTM

$92.57 -0.50 (-0.54%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$92.56 0.00 (-0.01%)

As of 10/30/2026 07:30 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHMMF, IOVA, RYTM, and LGND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHMMF, IOVA, RYTM, and LGND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHMMF, IOVA, RYTM, and LGND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHMMF, IOVA, RYTM, and LGND Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Ligand Pharmaceuticals NASDAQ:LGND

Pharma Mar OTCMKTS:PHMMF

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PHMMF, IOVA, RYTM, and LGND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PHMMF, IOVA, RYTM, and LGND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PHMMF, IOVA, RYTM, and LGND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHMMF, IOVA, RYTM, and LGND Company Descriptions

Iovance Biotherapeutics NASDAQ:IOVA

Ligand Pharmaceuticals NASDAQ:LGND

Pharma Mar OTCMKTS:PHMMF

Rhythm Pharmaceuticals NASDAQ:RYTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools